Cymabay Therapeutics Inc (NDAQ:CBAY) Price Target & New Coverage by Suntrust Robinson

In analysts report shared with investors on Friday, 18 August, research professionals at Suntrust Robinson has initiated coverage on shares of Cymabay Therapeutics Inc (NDAQ:CBAY). The firm set a Buy rating with $15.00, giving 139.23 % to target.

Cymabay Therapeutics Inc (NDAQ:CBAY) Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982.

Cymabay Therapeutics Inc (NDAQ:CBAY) traded up 0.32% on 18 August, hitting $6.26. A total of 946,717 shares of the company’s stock traded hands. This is down from average of 1.78 million shares. Cymabay Therapeutics Inc has a 52 week low of $1.15 and a 52 week high of $8.29. The company has a market cap of $273.92 million and a P/E ratio of 0.

Get the latest Cymabay Therapeutics Inc (NDAQ:CBAY) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Suntrust Robinson Initiates Coverage on Cymabay Therapeutics Inc (NDAQ:CBAY) with Buy and with $15.00 Target appeared first on Octafinance.